Drug intelligence / Profile preview

dehydrodiisoeugenol

Development stage: Preclinical
Modality: Small Molecules

Overview

Dehydrodiisoeugenol is a naturally occurring lignan with anti-inflammatory, anti-bacterial, antioxidant, and anticancer properties. It inhibits LPS-stimulated NF-κB activation and cyclooxygenase (COX)-2 gene expression in murine macrophages. It targets the PLK1-p53 axis to inhibit cancer cell proliferation.

Other names: Diisoeugenol, dehydro-Isoeugenol, dehydrodi-NSC 16743NSC16743NSC-16743

Targets

TP53 (Cellular Tumor Antigen p53 R175H)

Beyond the preview

Go deeper on dehydrodiisoeugenol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dehydrodiisoeugenol.

Explore the full profile